Quotient Sciences announced the launch of Arcinova - a science-driven service brand for early development that will operate within Quotient Sciences.
Arcinova offer integrated drug substance and drug product capabilities for early development, bioanalysis, isotope labelling, and microbiology services from facilities in Reading and Alnwick, UK. As specialty areas, Arcinova also support inhaled drug product development and aseptic manufacturing, and will continue to explore mRNA as an innovation area following the announcement made last year about the installation of the Centillion equipment in Alnwick.
Arcinova's services complement those that continue to be offered from Quotient Sciences, such as the Translational Pharmaceutics platform which uniquely integrates both clinical and manufacturing services.
In addition, Quotient has formed a new scientific advisory board that includes:
- Dr. Dominique Demolle, CEO of Cognivia: Dr. Demolle co-founded Cognivia to apply machine learning and patient psychology to clinical trials and was named one of PharmaVoice’s Most Inspiring People in Life Sciences in 2022.
- Dr. Alastair Coupe, Independent CMC Consultant: Following a 25+ career at Pfizer, Dr. Coupe is a recognized leader in drug development and regulatory strategy, having led major initiatives in pediatric formulation and nitrosamine risk mitigation.
- Dr. Colin Rowlings, SVP of CMC at Actio Biosciences: Dr. Rowlings has guided CMC strategy at companies including Gossamer Bio and Ardea Biosciences, and as a consultant has contributed to the development of diverse dosage forms and enabling technologies at over 30 biotech firms.
- Professor Yvonne Perrie, Chair in Drug Delivery at the University of Strathclyde: A leading academic in drug and vaccine delivery, Professor Perrie has authored over 150 publications and was appointed MBE in 2024 for her contributions to pharmaceutical innovation and regulation.